de Vrueh RL[au] - Search Results

Year	Number of Results
1996	1
1997	1
1998	3
1999	1
2000	4
2001	3
2008	2
2009	1
2010	1
2011	1
2013	2
2014	1
2017	1
2019	1
2024	0

1

Editorial: Public-Private Partnerships as Drivers of Innovation in Healthcare.

de Vrueh RLA, de Vlieger JSB, Crommelin DJA. de Vrueh RLA, et al. Front Med (Lausanne). 2019 May 31;6:114. doi: 10.3389/fmed.2019.00114. eCollection 2019. Front Med (Lausanne). 2019. PMID: 31214590 Free PMC article. No abstract available.

2

Reflections on the Future of Pharmaceutical Public-Private Partnerships: From Input to Impact.

de Vrueh RLA, Crommelin DJA. de Vrueh RLA, et al. Pharm Res. 2017 Oct;34(10):1985-1999. doi: 10.1007/s11095-017-2192-5. Epub 2017 Jun 6. Pharm Res. 2017. PMID: 28589444 Free PMC article. Review.

3

Orphan drug development across Europe: bottlenecks and opportunities.

Heemstra HE, de Vrueh RL, van Weely S, Büller HA, Leufkens HG. Heemstra HE, et al. Among authors: de vrueh rl. Drug Discov Today. 2008 Aug;13(15-16):670-6. doi: 10.1016/j.drudis.2008.05.001. Epub 2008 Jun 24. Drug Discov Today. 2008. PMID: 18583178 Review.

4

Recombinant lipoproteins: lipoprotein-like lipid particles for drug targeting.

Rensen PC, de Vrueh RL, Kuiper J, Bijsterbosch MK, Biessen EA, van Berkel TJ. Rensen PC, et al. Among authors: de vrueh rl. Adv Drug Deliv Rev. 2001 Apr 25;47(2-3):251-76. doi: 10.1016/s0169-409x(01)00109-0. Adv Drug Deliv Rev. 2001. PMID: 11311995 Review.

5

Towards the harmonization of outcome measures in children with mitochondrial disorders.

Koene S, Jansen M, Verhaak CM, De Vrueh RL, De Groot IJ, Smeitink JA. Koene S, et al. Among authors: de vrueh rl. Dev Med Child Neurol. 2013 Aug;55(8):698-706. doi: 10.1111/dmcn.12119. Epub 2013 Mar 12. Dev Med Child Neurol. 2013. PMID: 23489006 Free article. Review.

6

Translation of rare disease research into orphan drug development: disease matters.

Heemstra HE, van Weely S, Büller HA, Leufkens HG, de Vrueh RL. Heemstra HE, et al. Among authors: de vrueh rl. Drug Discov Today. 2009 Dec;14(23-24):1166-73. doi: 10.1016/j.drudis.2009.09.008. Epub 2009 Oct 7. Drug Discov Today. 2009. PMID: 19818412 Review.

7

Targeting hepatitis B therapy to the liver. Clinical pharmacokinetic considerations.

Rensen PC, de Vrueh RL, van Berkel TJ. Rensen PC, et al. Among authors: de vrueh rl. Clin Pharmacokinet. 1996 Aug;31(2):131-55. doi: 10.2165/00003088-199631020-00005. Clin Pharmacokinet. 1996. PMID: 8853935 Review.

8

Deal watch: Roles and strategies for health foundations in public-private partnerships.

de Vrueh RL, Awad W, Stolk A, Dijcks FA, Rijnders TW, Janssen JW. de Vrueh RL, et al. Nat Rev Drug Discov. 2014 Jun;13(6):406. doi: 10.1038/nrd4340. Nat Rev Drug Discov. 2014. PMID: 24875086 No abstract available.

9

Drug development for exceptionally rare metabolic diseases: challenging but not impossible.

Putzeist M, Mantel-Teeuwisse AK, Wied CC, Hoes AW, Leufkens HG, de Vrueh RL. Putzeist M, et al. Among authors: de vrueh rl. Orphanet J Rare Dis. 2013 Nov 15;8:179. doi: 10.1186/1750-1172-8-179. Orphanet J Rare Dis. 2013. PMID: 24237580 Free PMC article.

10

Predictors of orphan drug approval in the European Union.

Heemstra HE, de Vrueh RL, van Weely S, Büller HA, Leufkens HG. Heemstra HE, et al. Among authors: de vrueh rl. Eur J Clin Pharmacol. 2008 May;64(5):545-52. doi: 10.1007/s00228-007-0454-6. Epub 2008 Jan 22. Eur J Clin Pharmacol. 2008. PMID: 18210097 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Results by year

Text availability

Article attribute

Article type

Publication date

23 results

Results by year

Search Page

Filters

My NCBI Filters

Results by year

Text availability

Article attribute

Article type

Publication date

Search Results

23 results

Results by year